Comparative Pharmacology
Head-to-head clinical analysis: PONLIMSI versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONLIMSI versus TEPMETKO.
PONLIMSI vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
450 mg orally once daily with food.
None Documented
None Documented
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor